PARASOL
PROTEINURIA AND GFR AS CLINICAL TRIAL ENDPOINTS IN FOCAL SEGMENTAL GLOMERULOSCLEROSIS
PUBLIC SCIENTIFIC WORKSHOP: OCTOBER 7–8
The PARASOL workgroup will present key findings on proteinuria and GFR as clinical trial endpoints for FSGS in a public scientific workshop co-sponsored by the FDA, ISGD, NephCure, KHI, and NKF.BACKGROUND
FSGS is a rare kidney disease that affects patients of all ages and has a high risk of progression to kidney failure. There are no FDA-approved therapies for this disease. Thus, there is an urgent need to conduct randomized clinical trials and to develop safe and effective therapies for FSGS. While the FDA currently accepts a complete remission or near normalization of proteinuria as a surrogate endpoint and basis for traditional approval of new treatments for FSGS, further work is needed to support the use of lesser changes in proteinuria as a basis for accelerated or traditional approval.
The PARASOL project builds upon and continues the important foundational work in this area conducted since 2019 by the Kidney Health Initiative (KHI).
OBJECTIVES
The PARASOL group will achieve this in 2024 by conducting a large-scale analysis of existing data from patients of all ages with FSGS who are participants in observational cohort studies, regional or national registries, or real-world data sets. The project is sponsored by NephCure, the International Society of Glomerular Disease, the Kidney Health Initiative, and the National Kidney Foundation. The data analysis is led by a team from the Michigan Kidney Translational Medicine Center at the University of Michigan.
NEWS
- Join us on October 7-8 in Bethesda, Maryland (or virtually) for a public Scientific Workshop where the PARASOL team will present the results of their analysis.
- The PARASOL results will also be presented at ASN Kidney Week on October 25, 2024.
- Read an update from our interim meeting in Kidney News (August 2024).
- The organizing team held webinars on March 13-14 to introduce the project, provide progress updates, and answer questions. The content is especially geared toward industry, but accessible to all. Access the replay or download slides here.
- Watch our video about the goals of PARASOL:
- Read about PARASOL in the February 2024 issue of ASN's Kidney News: Community Collaborates to Address Clinical Trial Endpoints for FSGS
ORGANIZING COMMITTEE
- Matthias Kretzler, MD, University of Michigan (Co-Chair)
- Laura Mariani, MD, MSCE, FASN, University of Michigan (Co-Chair)
- Laurel Damashek, MA, International Society of Glomerular Disease
- Lauren Eva, NephCure
- Barbara Gillespie, MD, Fortrea; Adjunct Professor, UNC
- Tobias B. Huber, MD, International Society of Glomerular Disease and University Medical Center Hamburg-Eppendorf
- Alex Mercer, PhD, JAMCO Pharma Consulting
- Glory Onwuka, MS, International Society of Glomerular Disease
- Abigail Smith, PhD, Northwestern University
- Josh Tarnoff, NephCure
- Aliza Thompson, MD, MS, FDA
- Howard Trachtman, MD, University of Michigan
- Hailey Desmond, MS, University of Michigan
- Melissa West, American Society of Nephrology (Kidney Health Initiative)
- Kerry Willis, PhD, National Kidney Foundation
CONTACT THE PROJECT TEAM
Please contact the PARASOL team if you have any questions about the project, are interested in contributing data, or would like to participate in another way.
Laura Mariani, MD, MSCE
Associate Professor of Medicine, University of Michigan
lmariani@med.umich.edu
Laurel Damashek
Executive Director, International Society of Glomerular Disease
ldamashek@is-gd.org
SPONSORS
.png?width=300&name=NKF%20clear%20background%20(2000%20x%20500%20px).png)
